CHI3L1 and COVID-19: The researchers also reported that although systemic inflammation had returned to baseline levels and plasma CHI3L1 levels decreased after 4 weeks of clinical remission in the patients with COVID-19,CHI3L1 levels in individuals that recently presented with systemic inflammation were significantly higher than those in healthy controls.